Summary
2023 Europe Blood Typing, Grouping and Infectious Disease NAT Screening Market--France, Germany, Italy, Spain, UK--2022 Supplier Shares and Strategies by Country, 2022-2027 Volume and Sales Segment Forecasts for over 40 Individual Immunohematology and NAT Assays
This unique report provides information and analysis not available from any other published source.
The report is available by section, and can be customized to specific information needs and budget.
The database provides the 2022 supplier shares and strategies by country, the 2022-2027 volume and sales forecasts for over 40 immunohematology and NAT assays, as well as comprehensive lists of companies developing or marketing new technologies and products by test, including:
ABO, Antibody Panels, Antibody Screening/Indirect Antiglobulin, Antigen Typing (C, c, Duffy, E, e, I, i, Kell, Kidd, Le a, b, MN, P, S, s), Antiglobulin (Direct, C3 + IgG, IgG, C3), Crossmatching (Immediate Spin, Full Crossmatch), Rh (D, Du)
Infectious Disease Screening Tests
AIDS (HIV NAT, HIV-1/2), Cytomegalovirus, Hepatitis (HAV NAT, HBV NAT, HBs Ag, Anti-HBc, HCV NAT, HCV, ALT/SGPT), HTLV-I/II, Parvovirus B19 NAT, Syphilis, West Nile Virus NAT
Geographic Regions
France, Germany, Italy, Spain, UK
The companies analyzed in the report include:- Abbott
- Beckman Coulter/Danaher
- Becton Dickinson
- Biokit
- bioMerieux
- Bio-Rad
- Diagast
- DiaSorin
- Fujirebio
- Grifols
- Hologic
- Immucor
- LabCorp
- Proteome Sciences
- Quest Diagnostics
- QuidelOrtho
- Roche
- Siemens Healthineers
- Tecan
- Thermo Fisher